The effect of curcumin on the prevention of paclitaxel and platinum compounds-induced neuropathy in cancer patients
Phase 3
- Conditions
- Chemotherapy induced neuropathy.
- Registration Number
- IRCT20191106045356N6
- Lead Sponsor
- Yazd University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Age 20-50 years
Initiation of the treatment with paclitaxel and platinum compounds in cancer patients
Exclusion Criteria
History of allergy to curcumin or turmeric
Having diseases that cause neuropathy such as diabetes or conditions such as alcoholism.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The neuropathy score is determined based on the Michigan Neuropathy Screening Instrument (MNSI) questionnaire, which includes a test with 20 yes / no questions. Timepoint: Days 1, 4, 7, 14, 28 science starting internention. Method of measurement: Patient examination and Michigan Neuropathy Screening Instrument (MNSI) questionnaire.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie curcumin's neuroprotective effects against paclitaxel and platinum-induced neuropathy?
How does curcumin compare to standard-of-care agents like gabapentin in preventing chemotherapy-induced neuropathy?
Which biomarkers correlate with curcumin efficacy in mitigating paclitaxel/platinum-induced neurotoxicity?
What adverse events are associated with curcumin supplementation during paclitaxel and platinum-based chemotherapy?
Are there synergistic effects of curcumin with other neuroprotectants in managing chemotherapy-induced peripheral neuropathy?